Login / Signup

Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer.

Norma B BulamuChristine Mpundu-KaambwaMichael E O'CallaghanBillingsley Kaambwa
Published in: BMC cancer (2023)
AQoL-6D can be used in combination with EPIC-26 in place of SF-12. Although EPIC-26 is not utility based, its popularity amongst clinicians and ability to discriminate between disease-specific characteristics and post-treatment outcomes in clinical trials makes it a candidate for use within cost-effectiveness analyses. The generic measure provides a holistic assessment of quality of life and is suitable for generating quality adjusted life years (QALYs).
Keyphrases
  • prostate cancer
  • clinical trial
  • radical prostatectomy
  • palliative care
  • randomized controlled trial
  • combination therapy
  • open label
  • study protocol
  • phase iii